Treatment of muscle-invasive bladder cancer: A systematic review

Cancer

Volumn 122, Issue 6, 2016, Pages 842-851

  Chou, Roger ^a   Selph, Shelley S ^a   Buckley, David I ^a   Gustafson, Katie S ^a   Griffin, Jessica C ^a   Grusing, Sara E ^a   Gore, John L ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

adjuvant chemotherapy; bladder cancer; bladder sparing therapy; lymph node dissection; neoadjuvant chemotherapy; radical cystectomy

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE; VINBLASTINE; ANTINEOPLASTIC AGENT;

CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; CYSTECTOMY; DRUG EFFICACY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LYMPH NODE DISSECTION; MUSCLE INVASIVE BLADDER CANCER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SURGICAL APPROACH; SURGICAL TECHNIQUE; SYSTEMATIC REVIEW; TRANSURETHRAL RESECTION; ADJUVANT CHEMOTHERAPY; CONSERVATIVE TREATMENT; EVIDENCE BASED MEDICINE; MORTALITY; NEOADJUVANT THERAPY; PATHOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR INVASION; URINARY BLADDER NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYSTECTOMY; EVIDENCE-BASED MEDICINE; HUMANS; LYMPH NODE EXCISION; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; ORGAN SPARING TREATMENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84960329940     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29843     Document Type: Review

References (65)

1. Siegel R, Ma J, Zou Z, Jemal A,. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9-29.
2. American Cancer Society. Bladder cancer. http://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer-staging. Accessed October 16, 2013.
3. Kaufman DS, Shipley WU, Feldman AS,. Bladder cancer. Lancet. 2009; 374: 239-249.
4. Witjes JA, Comperat E, Cowan NC, et al., Guidelines on muscle-invasive and metastatic bladder cancer, 2015. http://uroweb.org/wp-content/uploads/EAU-Guidelines-Muscle-invasive-and-Metastatic-Bladder-Cancer-0000-v1.pdf. Accessed December 7, 2015.
5. Herr HW,. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol. 2001; 19: 89-93.
6. Chou R, Selph S, Buckley D, et al,; Pacific Northwest Evidence-based Practice Center. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer. Comparative Effectiveness Review. Rockville, MD: Agency for Healthcare Research and Quality; 2015.
7. Agency for Healthcare Research and Quality. Methods guide for effectiveness and comparative effectiveness reviews 2014. www.effectivehealthcare.ahrq.gov. Accessed April 4, 2014.
8. Chou R, Selph S, Gore J, et al., Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer. 2015, PROSPERO International prospective register of systematic reviews, CRD42014013282. http://www.crd.york.ac.uk/prospero/display-record.asp?ID=CRD42014013282. Accessed December 8, 2015.
9. US Preventive Services Task Force. Procedure manual. http://www.uspreventiveservicestaskforce.org/uspstf08/methods/procmanual.htm. Accessed April 4, 2014.
10. Sell A, Jakobsen A, Nerstrom B, Sorensen BL, Steven K, Barlebo H,. Treatment of advanced bladder cancer category T2 T3 and T4a. A randomized multicenter study of preoperative irradiation and cystectomy versus radical irradiation and early salvage cystectomy for residual tumor. DAVECA protocol 8201. Danish Vesical Cancer Group. Scand J Urol Nephrol Suppl. 1991; 138: 193-201.
11. Bekelman JE, Handorf EA, Guzzo T, et al., Radical cystectomy versus bladder-preserving therapy for muscle-invasive urothelial carcinoma: examining confounding and misclassification bias in cancer observational comparative effectiveness research. Value Health. 2013; 16: 610-618.
12. Goossens-Laan CA, Leliveld AM, Verhoeven RH, et al., Effects of age and comorbidity on treatment and survival of patients with muscle-invasive bladder cancer. Int J Cancer. 2014; 135: 905-912.
13. Holmang S, Hedelin H, Anderstrom C, Johansson SL,. Long-term followup of all patients with muscle invasive (stages T2, T3 and T4) bladder carcinoma in a geographical region. J Urol. 1997; 158: 389-392.
14. Kalogeras D, Lampri E, Goussia A, et al., Radical therapy for muscle-infiltrating bladder cancer (cystectomy or radiotherapy): does age affect the final therapeutic benefit for the patient? J BUON. 2008; 13: 353-358.
15. Kotwal S, Choudhury A, Johnston C, Paul AB, Whelan P, Kiltie AE,. Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center. Int J Radiat Oncol Biol Phys. 2008; 70: 456-463.
16. Nieuwenhuijzen JA, Pos F, Moonen LM, Hart AM, Horenblas S,. Survival after bladder-preservation with brachytherapy versus radical cystectomy; a single institution experience. Eur Urol. 2005; 48: 239-245.
17. Rincon Mayans A, Rosell Costa D, Zudaire Bergera JJ, et al., Response and progression-free survival in T2 to T4 bladder tumors treated with trimodality therapy with bladder preservation [in Spanish]. Acta Urol Esp. 2010; 34: 775-780.
18. Solsona E, Climent MA, Iborra I, et al., Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy. Eur Urol. 2009; 55: 911-919.
19. James ND, Hussain SA, Hall E, et al., Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012; 366: 1477-1488.
20. Abdollah F, Sun M, Schmitges J, et al., Stage-specific impact of pelvic lymph node dissection on survival in patients with non-metastatic bladder cancer treated with radical cystectomy. BJU Int. 2012; 109: 1147-1154.
21. Herr HW, Bochner BH, Dalbagni G, Donat SM, Reuter VE, Bajorin DF,. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol. 2002; 167: 1295-1298.
22. Konety BR, Joslyn SA, O'Donnell MA,. Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data base. J Urol. 2003; 169: 946-950.
23. Brossner C, Pycha A, Toth A, Mian C, Kuber W,. Does extended lymphadenectomy increase the morbidity of radical cystectomy? BJU Int. 2004; 93: 64-66.
24. Brunocilla E, Pernetti R, Schiavina R, et al., The number of nodes removed as well as the template of the dissection is independently correlated to cancer-specific survival after radical cystectomy for muscle-invasive bladder cancer. Int Urol Nephrol. 2013; 45: 711-719.
25. Dhar NB, Klein EA, Reuther AM, Thalmann GN, Madersbacher S, Studer UE,. Outcome after radical cystectomy with limited or extended pelvic lymph node dissection. J Urol. 2008; 179: 873-878; discussion 878.
26. Leissner J, Hohenfellner R, Thuroff JW, Wolf HK,. Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. BJU Int. 2000; 85: 817-823.
27. Poulsen AL, Horn T, Steven K,. Radical cystectomy: extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall. J Urol. 1998; 160 (6 pt 1): 2015-2019; discussion 2020.
28. Zehnder P, Studer UE, Skinner EC, et al., Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. J Urol. 2011; 186: 1261-1268.
29. Simone G, Papalia R, Ferriero M, et al., Stage-specific impact of extended versus standard pelvic lymph node dissection in radical cystectomy. Int J Urol. 2013; 20: 390-397.
30. Herr HW, Faulkner JR, Grossman HB, et al., Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol. 2004; 22: 2781-2789.
31. Shirotake S, Kikuchi E, Matsumoto K, Yazawa S, Kosaka T, MIyajima A, Nakagawa K, Oya M,. Role of pelvic lymph node dissection in lymph node-negative patients with invasive bladder cancer. Jpn J Clin Oncol. 2010; 40: 247-251.
32. Grossman HB, Natale RB, Tangen CM, et al., Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003; 349: 859-866.
33. Kitamura H, Tsukamoto T, Shibata T, et al,; Urologic Oncology Study Group of the Japan Clinical Oncology Group. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209. Ann Oncol. 2014; 25: 1192-1198.
34. Sengelov L, von der Maase H, Lundbeck F, et al., Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumours. Acta Oncol. 2002; 41: 447-456.
35. Sherif A, Rintala E, Mestad O, et al,; Nordic Urothelial Cancer Group. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer-Nordic cystectomy trial 2. Scand J Urol Nephrol. 2002; 36: 419-425.
36. Malmstrom PU, Rintala E, Wahlqvist R, Hellstrom P, Hellsten S, Hannisdal E,. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol. 1996; 155: 1903-1906.
37. Rintala E, Hannisdahl E, Fossa SD, Hellsten S, Sander S,. Neoadjuvant chemotherapy in bladder cancer: a randomized study. Nordic Cystectomy Trial I. Scand J Urol Nephrol. 1993; 27: 355-362.
38. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet. 1999; 354: 533-540.
39. International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011; 29: 2171-2177.
40. Fairey AS, Daneshmand S, Quinn D, et al., Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California. Urol Oncol. 2013; 31: 1737-1743.
41. Pal SK, Ruel NH, Wilson TG, Yuh BE,. Retrospective analysis of clinical outcomes with neoadjuvant cisplatin-based regimens for muscle-invasive bladder cancer. Clin Genitourin Cancer. 2012; 10: 246-250.
42. Yeshchina O, Badalato GM, Wosnitzer MS, et al., Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder. Urology. 2012; 79: 384-390.
43. Freiha F, Reese J, Torti FM,. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol. 1996; 155: 495-499; discussion 499-500.
44. Cognetti F, Ruggeri EM, Felici A, et al,; Study Group. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. Ann Oncol. 2012; 23: 695-700.
45. Bono AV, Benvenuti C, Gibba A, et al., Adjuvant chemotherapy in locally advanced bladder cancer. Final analysis of a controlled multicentre study. Acta Urol Ital. 1997; 11: 5-8.
46. Skinner DG, Daniels JR, Russell CA, et al., The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol. 1991; 145: 459-464; discussion 464-467.
47. Millikan R, Dinney C, Swanson D, et al., Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol. 2001; 19: 4005-4013.
48. Wosnitzer MS, Hruby GW, Murphy AM, et al., A comparison of the outcomes of neoadjuvant and adjuvant chemotherapy for clinical T2-T4aN0-N2M0 bladder cancer. Cancer. 2012; 118: 358-364.
49. Matsubara N, Mukai H, Naito Y, Nezu M, Itoh K,. Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer. Asia Pac J Clin Oncol. 2013; 9: 310-317.
50. Mitin T, Shipley WU, Efstathiou JA, et al., Trimodality therapy for bladder conservation in treatment of invasive bladder cancer. Curr Urol Rep. 2013; 14: 109-115.
51. Gakis G, Efstathiou J, Lerner SP, et al,; International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012. ICUD-EAU International Consultation on Bladder Cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013; 63: 45-57.
52. Bruins HM, Veskimae E, Hernandez V, et al., The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic review. Eur Urol. 2014; 66: 1065-1077.
53. Mandel P, Tilki D, Eslick GD,. Extent of lymph node dissection and recurrence-free survival after radical cystectomy: a meta-analysis. Urol Oncol. 2014; 32: 1184-1190.
54. Pabla N, Dong Z,. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008; 73: 994-1007.
55. Advanced Bladder Cancer Meta-analysis Collaboration. Neo-adjuvant chemotherapy for invasive bladder cancer. Cochrane Database Syst Rev. 2004;(1): CD005246.
56. Song F, Khan KS, Dinnes J, Sutton AJ,. Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. Int J Epidemiol. 2002; 31: 88-95.
57. Deeks JJ, Macaskill P, Irwig L,. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005; 58: 882-893.
58. Parkinson JP, Konety BR,. Health related quality of life assessments for patients with bladder cancer. J Urol. 2004; 172 (6 pt 1): 2130-2136.
59. ClinicalTrials.gov. Southwest Oncology Group Trial S1011: standard or extended pelvic lymphadenectomy in treating patients undergoing surgery for invasive bladder cancer. https://clinicaltrials.gov/ct2/show/NCT01224665. Accessed December 3, 2015.
60. Tilki D, Brausi M, Colombo R, et al., Lymphadenectomy for bladder cancer at the time of radical cystectomy. Eur Urol. 2013; 64: 266-276.
61. Kim SP, Karnes RJ,. Standard or extended lymphadenectomy in radical cystectomy: what metric of surgical quality for lymph node dissections matters in improving patient outcomes? Eur Urol. 2011; 60: 953-954.
62. Meeks JJ, Bellmunt J, Bochner BH, et al., A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2012; 62: 523-533.
63. Plimack ER, Hoffman-Censits JH, Viterbo R, et al., Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol. 2014; 32: 1895-1901.
64. Choueiri TK, Jacobus S, Bellmunt J, et al., Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014; 32: 1889-1894.
65. ClinicalTrials.gov. Southwest Oncology Group Trial S1314: co-expression extrapolation (COXEN) program to predict chemotherapy response in patients with bladder cancer. https://clinicaltrials.gov/ct2/show/NCT02177695. Accessed December 3, 2015.